Statements (32)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
antiviral drug
neuraminidase inhibitor |
| gptkbp:administeredBy |
intravenous injection
|
| gptkbp:approvedBy |
gptkb:FDA
2014 |
| gptkbp:ATCCode |
J05AH02
|
| gptkbp:brand |
gptkb:Rapivab
|
| gptkbp:CASNumber |
330600-85-6
|
| gptkbp:developedBy |
gptkb:BioCryst_Pharmaceuticals
|
| gptkbp:eliminationHalfLife |
20 hours
|
| gptkbp:excretion |
renal
|
| gptkbp:hasInChIKey |
Q1J8A4N5FD
|
| gptkbp:hasMolecularFormula |
C15H28N4O4
|
| gptkbp:hasSMILES |
CC(C)CC(C(=O)NC(CC1=CN=C(N=C1)N)C(=O)O)O
|
| https://www.w3.org/2000/01/rdf-schema#label |
Peramivir
|
| gptkbp:KEGGID |
D08336
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
inhibits influenza virus neuraminidase
|
| gptkbp:metabolism |
not significantly metabolized
|
| gptkbp:PubChem_CID |
CHEMBL1201192
133332 151164 DB06614 |
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
diarrhea
hallucination delirium neutropenia |
| gptkbp:UNII |
Q1J8A4N5FD
|
| gptkbp:usedFor |
influenza treatment
|
| gptkbp:bfsParent |
gptkb:Influenza_Virus
|
| gptkbp:bfsLayer |
6
|